News
 
Email Page
Axinn Promotes Josh Reisberg to Partner, Bradley Justus and Matt Murphy to Counsel
January 1, 2019

Axinn announced today that Joshua Reisberg, a member in the firm’s Intellectual Property group, has been promoted to partner. Bradley Justus, a member in the firm’s Antitrust group, and Matthew Murphy, a member in the firm’s Intellectual Property group, have also been promoted to Counsel. The promotions were effective as of January 1, 2019.

“Josh, Bradley and Matthew are well-deserving of their promotions,” says Matthew Becker, Managing Partner of the firm. “Each allows his unique experience to inform his practice in novel ways that are nothing short of impressive. We congratulate each of them on their accomplishments so far and wholeheartedly expect that they will make further innovative and remarkable contributions to Axinn.” 

Based in the firm’s New York office, Josh Reisberg focuses his practice on intellectual property and high-stakes commercial litigation. His work has spanned a wide range of technologies over the years, including pharmaceuticals, medical devices, polymers, agricultural products, software and electronics. Reisberg’s experience also extends beyond the hard sciences into copyright, trademark and design patent disputes in the fashion, media and art industries.

Bradley Justus is based in the firm’s Washington, D.C. office and focuses his practice on antitrust law, including mergers, antitrust litigation, government investigations and counseling. He has significant experience in large global M&A transactions, appearing before the U.S. Department of Justice and Federal Trade Commission, in addition to representing clients in merger reviews by European, Brazilian, Canadian and Mexican competition regulators.

Matthew Murphy practices in intellectual property and patent litigation. Based in the firm’s Hartford office, he advises on complex patent issues as well as trade secrets disputes, sham litigation proceedings and other intellectual property matters. Prior to joining Axinn, Murphy spent seven years conducting research and development for pharmaceutical and medical device companies.